. 2017 Nov 9;8(68):112685–112696. doi: 10.18632/oncotarget.22340

Table 4. Univariate and multivariate Cox regression analyses of potential prognostic factors for MM.

Variable	Progression-free survival				Overall survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95 % CI)	p	HR (95 % CI)	p	HR (95 % CI)	p	HR (95 % CI)	p
Gender	1.00 (0.67-1.5)	1.00	0.83 (0.48-1.45)	0.52	1.13 (0.77-1.65)	0.54	0.70 (0.40-1.22)	0.21
Age	1.01 (0.99-1.0)	0.26	1.01 (0.98-1.03)	0.52	1.01 (0.99-1.03)	0.17	1.01 (0.98-1.03)	0.67
ISS^a		™0.12		0.11		0.002		0.001
II vs. I	1.21 (0.57-3.2)	0.63	1.32 (0.61-2.86)	0.49	0.79 (0.35-1.79)	0.57	1.01 (0.43-2.32)	0.94
III vs. I	1.76 (0.95-1.8)	0.08	1.87 (0.98-3.54)	0.06	2.05 (1.12-3.76)	0.02	2.41 (1.29-4.50)	0.006
Creatinine	1.16 (0.77-1.7)	0.48	1.12 (0.71-1.76)	0.63	1.27 (0.86-1.84)	0.224	1.13 (0.74-1.71)	0.57
LDH	0.99 (0.65-1.5)	0.97	1.19 (0.64-2.21)	0.58	1.26 (0.86-1.85)	0.241	1.62 (0.90-2.92)	0.11
iNOS⁺ TAMs (high vs. low)	0.74 (0.49-1.1)	0.16	0.78 (0.51-1.19)	0.25	0.50 (0.34-0.75)	0.001	0.57 (0.38-0.86)	0.007
CD163⁺ TAMs (high vs. low)	1.86 (1.23-2.8)	0.003	1.84 (1.20-2.83)	0.005	2.93 (2.00-4.30)	< 0.001	2.87 (1.93-4.26)	< 0.001
iNOS/CD163 signature^b		0.02		0.025		< 0.001		< 0.001
II vs. I	1.37 (0.80-2.3)	0.25	1.31 (0.76-2.25)	0.33	1.58 (0.90-2.78)	0.11	1.47 (0.83-2.60)	0.19
III vs. I	2.03 (1.08-3.8)	0.03	1.91 (1.00-3.65)	0.05	2.35 (1.22-4.50)	0.01	2.26 (1.16-4.44)	0.017
IV vs. I	2.30 (1.31-4.0)	0.004	2.35 (1.31-4.24)	0.004	4.73 (2.80-8.00)	< 0.001	4.75 (2.76-8.16)	< 0.001

HR hazard ratio, 95 % CI 95 % confidence interval, ISS International Staging System, LDH lactate dehydrogenase, TAMs tumor associated macrophages. ^a Reference group. ^b Patients were classified into four groups according to their iNOS and CD163 TAM densities: group I, high iNOS⁺ but low CD163⁺ TAM densities; group II, both low densities; group III, both high densities; group IV, low iNOS⁺ but high CD163⁺ TAM densities.